Jasmina Marjanovic
Direttore/Membro del Consiglio presso New England Venture Capital Association, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Kevin Bitterman | M | 47 |
New England Venture Capital Association, Inc.
 New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | 7 anni |
| Lily Lyman | F | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | 2 anni |
| Katie Fanning | F | - |
Mozart Therapeutics, Inc.
 Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Stephen Kraus | M | 47 |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Neil Exter | M | 65 |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Liam Donohue | M | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Anna Palmer | F | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | 1 anni |
| Marian Nakada | M | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | 7 anni |
| Peter Dudek | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 4 anni |
| Stefan Vitorovic | M | 39 |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | 1 anni |
| Colleen Cuffaro | M | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Ben Auspitz | M | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Nancy Brown | F | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Margarita I. Chavez | F | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Lucio Iannone | M | 41 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 3 anni |
| Julie Gilmore | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Jan Beck | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 2 anni |
| Marie-Claire Peakman | F | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 1 anni |
| Lisette Tellez | F | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Melissa Gilliam | M | 58 |
The University of Chicago
| 19 anni |
| Joshua Resnick | M | 49 |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Yumin Choi | M | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | 7 anni |
| Darshana Zaveri | F | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | 1 anni |
| Steven Gillis | M | 71 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Michael Walter Vannier | M | 75 |
The University of Chicago
| 20 anni |
| Jeffrey Bussgang | M | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | 7 anni |
| Ellen Rubin | F | 55 |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Thomas Daniel | M | 70 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 4 anni |
| Dayna Grayson | F | 47 |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Murat Bicer | M | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Ben Bailey | M | 75 |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Richard Bennett | M | 46 |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | 1 anni |
| Johannes Nielsen | M | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Rudina Seseri | F | 46 |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | 1 anni |
| Sara Nayeem | M | 75 |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
| Henrijette Richter | M | 53 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| K. Christopher Garcia | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Ari Glantz | M | - |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Hoossam Malek | M | - |
The University of Chicago
| 3 anni |
| Laszlo Korsos | M | - |
The University of Chicago
| 5 anni |
| Hays Golden | M | 39 |
The University of Chicago
| 11 anni |
| Jason L. Wyman | M | - |
The University of Chicago
| 8 anni |
| Lukasz Pomorski | M | - |
The University of Chicago
| 3 anni |
| Amer Hasan | M | - |
The University of Chicago
| 7 anni |
| Kimerling Daniel | M | - |
The University of Chicago
| 4 anni |
| Feng Li | M | 48 |
The University of Chicago
| 3 anni |
| Taylor Feehley | M | - |
The University of Chicago
| 10 anni |
| Bradley Mills Feingerts | M | - |
The University of Chicago
| 4 anni |
| Ke Cheng | M | - |
The University of Chicago
| 3 anni |
| John Scotti | M | - |
The University of Chicago
| 4 anni |
| Rodney Nelson | M | - |
The University of Chicago
| 4 anni |
| Charles Hachten | M | - |
The University of Chicago
| 9 anni |
| James Crown | M | 70 |
The University of Chicago
| 18 anni |
| Matt Hutchison | M | - |
The University of Chicago
| 3 anni |
| Gerald S. Tannenbaum | M | - |
The University of Chicago
| 7 anni |
| Peishan Tan | M | - |
The University of Chicago
| 5 anni |
| Oleg Gurin | M | - |
The University of Chicago
| 2 anni |
| Jeremy Evan Milim | M | - |
The University of Chicago
| 2 anni |
| Andrew Curran Ross | M | - |
The University of Chicago
| 2 anni |
| Eric Guzman | M | - |
The University of Chicago
| 2 anni |
| Paul Jordan Arnold | M | 41 |
The University of Chicago
| 3 anni |
| Alec Nicholas Lance | M | - |
The University of Chicago
| 4 anni |
| Ali Sheikh | M | - |
The University of Chicago
| 4 anni |
| Deva Meenakshisundaram | M | - |
The University of Chicago
| 4 anni |
| Emily Xia-Reinert | F | - |
The University of Chicago
| 4 anni |
| Travis J. Krueger | M | - |
The University of Chicago
| 3 anni |
| Joshua D. Kramer | M | - |
The University of Chicago
| 2 anni |
| Samuel Everritt Miller | M | - |
The University of Chicago
| 3 anni |
| Ana M. Winters | F | - |
The University of Chicago
| 2 anni |
| Matthew John Adams | M | - |
The University of Chicago
| 2 anni |
| Dan D. Schlemmer | M | - |
The University of Chicago
| 2 anni |
| Marta Melar New | M | 44 |
University of Novi Sad
| 4 anni |
| Jonathan Ho | M | - |
The University of Chicago
| 2 anni |
| Koh Kim | F | - |
The University of Chicago
| 4 anni |
| Jae Chang | F | - |
The University of Chicago
| 4 anni |
| Jamil Haque Soriano | M | - |
The University of Chicago
| 2 anni |
| Scott Shih Yau Shiao | M | - |
The University of Chicago
| 2 anni |
| Eric Fishel | M | - |
The University of Chicago
| 2 anni |
| David Fei Fang | M | - |
The University of Chicago
| 4 anni |
| Pranay Gupta Laharia | M | - |
The University of Chicago
| 2 anni |
| Alexander Shire | M | - |
The University of Chicago
| 2 anni |
| Ryan Gembala | M | - |
The University of Chicago
| 2 anni |
| Shane Kokkines | M | - |
The University of Chicago
| 2 anni |
| Michael P. Jordan | M | - |
The University of Chicago
| 2 anni |
| Justin Lam | M | - |
The University of Chicago
| 4 anni |
| Chris Kocinski | M | - |
The University of Chicago
| 3 anni |
| Reed Singer | M | - |
The University of Chicago
| 2 anni |
| Diana S. Rashkow | F | - |
The University of Chicago
| 2 anni |
| Scott D. Kauffman | M | - |
The University of Chicago
| 2 anni |
| Imran Ahmad | M | - |
The University of Chicago
| 4 anni |
| Mike Gershowitz | M | - |
The University of Chicago
| 2 anni |
| Edward S. Su | M | - |
The University of Chicago
| 4 anni |
| Fred Lee | M | - |
The University of Chicago
| 2 anni |
| Ivana Delevska | F | - |
The University of Chicago
| 4 anni |
| Yana Krivozus | F | - |
The University of Chicago
| 4 anni |
| Steven Richard Ruh | M | - |
The University of Chicago
| 3 anni |
| Alfredo Pinel | M | - |
The University of Chicago
| 2 anni |
| Tyler Brown | M | - |
The University of Chicago
| 4 anni |
| Michael Melby | M | - |
The University of Chicago
| 2 anni |
| Yuujiro Goto | M | - |
The University of Chicago
| 12 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 99 | 99.00% |
| Serbia, Repubblica di | 1 | 1.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Jasmina Marjanovic
- Contatti personali
